David A. Siegel Vanda Pharmaceuticals Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 909,300 shares of VNDA stock, worth $3.96 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
909,300
Previous 809,200
12.37%
Holding current value
$3.96 Million
Previous $3.82 Million
18.8%
% of portfolio
0.01%
Previous 0.01%
Shares
33 transactions
Others Institutions Holding VNDA
# of Institutions
161Shares Held
45.5MCall Options Held
159KPut Options Held
229K-
Black Rock Inc. New York, NY8.14MShares$35.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.59MShares$15.6 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.48MShares$15.1 Million0.02% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.25MShares$14.1 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.56MShares$11.2 Million0.0% of portfolio
About Vanda Pharmaceuticals Inc.
- Ticker VNDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,561,500
- Market Cap $246M
- Description
- Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...